Related coverage linked through entity extraction aliases.
Apr 03, 2026
MacroGenics faces critical 2026 milestones for its ADC pipeline, including Phase 1 data for MGC026 and regulatory resolution for lorigerlimab. The company has financial runway through 2027 and plans IND submission for MGC030 in Q3 2026. Key investor events include ASCO abstract releases and financial results in Q2 2026.
Feb 15, 2026
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
Feb 14, 2026
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
